Abstract
Mutations in mitochondrial genes, oxidative insults, imbalance in redox mechanisms and dysregulated mitophagy are some of the leading causes for mitochondrial dysfunction and subsequent neurodegeneration in Parkinson’s disease. Targeting mitochondrial dysfunction and prolonging neuronal survival could potentially prove to be useful neuroprotective strategies. In some recent investigations, peroxisome proliferator activated receptor gamma coactivator 1 alpha mediated mitochondrial biogenesis and its ability to restore reactive oxygen species-detoxifying enzymes have been observed in preclinical studies. In this review, we discuss about physiological importance of peroxisome proliferator activated receptor gamma coactivator 1 alpha along with a list of its activators that could prove useful as possible neuroprotectants in Parkinson’s disease.
Keywords: Mitochondrial biogenesis, Mitochondrial transcription factor A, Neurodegeneration, Parkinson’s disease, Reactive oxygen species, Sirtuin 1.
CNS & Neurological Disorders - Drug Targets
Title:Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha: An Emerging Target for Neuroprotection in Parkinson’s Disease
Volume: 14 Issue: 8
Author(s): Nihar Ranjan Das and Shyam Sunder Sharma
Affiliation:
Keywords: Mitochondrial biogenesis, Mitochondrial transcription factor A, Neurodegeneration, Parkinson’s disease, Reactive oxygen species, Sirtuin 1.
Abstract: Mutations in mitochondrial genes, oxidative insults, imbalance in redox mechanisms and dysregulated mitophagy are some of the leading causes for mitochondrial dysfunction and subsequent neurodegeneration in Parkinson’s disease. Targeting mitochondrial dysfunction and prolonging neuronal survival could potentially prove to be useful neuroprotective strategies. In some recent investigations, peroxisome proliferator activated receptor gamma coactivator 1 alpha mediated mitochondrial biogenesis and its ability to restore reactive oxygen species-detoxifying enzymes have been observed in preclinical studies. In this review, we discuss about physiological importance of peroxisome proliferator activated receptor gamma coactivator 1 alpha along with a list of its activators that could prove useful as possible neuroprotectants in Parkinson’s disease.
Export Options
About this article
Cite this article as:
Das Ranjan Nihar and Sharma Sunder Shyam, Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha: An Emerging Target for Neuroprotection in Parkinson’s Disease, CNS & Neurological Disorders - Drug Targets 2015; 14 (8) . https://dx.doi.org/10.2174/1871527314666150326000018
DOI https://dx.doi.org/10.2174/1871527314666150326000018 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurodegenerative Disorders and the Current State, Pathophysiology, and
Management of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Biological Targets of Antitumor Indolocarbazoles Bearing a Sugar Moiety
Current Medicinal Chemistry - Anti-Cancer Agents Polyamine Modulation of NMDARs as a Mechanism to Reduce Effects of Alcohol Dependence
Recent Patents on CNS Drug Discovery (Discontinued) Targeting ErbB Receptors in High-Grade Glioma
Current Pharmaceutical Design Dietary Fat and Hypertension: A Novel Approach Through the Proteolytic Regulatory Enzymes of the Renin-Angiotensin-System
Cardiovascular & Hematological Agents in Medicinal Chemistry Extranuclear Localization of SIRT1 and PGC-1α: An Insight into Possible Roles in Diseases Associated with Mitochondrial Dysfunction
Current Molecular Medicine Mitochondrial Permeability Transition as Target of Anticancer Drugs
Current Pharmaceutical Design Mechanism of CNS Drugs and their Combinations for Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Good, Bad, Mobile Elements: Genome’s Most Successful “Parasites” as Emerging Players in Cell and Organismal Aging
Current Pharmaceutical Design Editorial (Thematic Issue: Focal Adhesion Kinase and Cross-Linked Signaling In Cancer)
Anti-Cancer Agents in Medicinal Chemistry Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs
Current Topics in Medicinal Chemistry PACAP and Its Receptors Exert Pleiotropic Effects in The Nervous System by Activating Multiple Signaling Pathways
Current Protein & Peptide Science Disintegrins from Snake Venoms and their Applications in Cancer Research and Therapy
Current Protein & Peptide Science The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Solid Phase Synthesis of Oxytocin Analogues Conjugated to Polyamino Polycarboxylic Ligands
Letters in Organic Chemistry Hypoxic Tumor Microenvironment and Cancer Cell Differentiation
Current Molecular Medicine RNAi Applications in Therapy Development for Neurodegenerative Disease
Current Pharmaceutical Design Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer’s Disease
Current Neuropharmacology Pharmacological Targets for the Inhibition of Neurogenic Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents